Vimarsana
Biggest News Aggregation in the World

Page 10 - Instil Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Instil Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Instil Bio Today - Breaking & Trending Today

Life Sciences Real Estate Update - August 2022 | Allen Matkins - Vimarsana News

Life Sciences Real Estate Update - August 2022 | Allen Matkins

JLL report predicts wave of demand for biotech space - Propmodo – July 10 - The latest figures on gene and cell therapy research show a record number of regulatory approvals in 2022,...

Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

12.08.2022 - Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational intent anticipated to complete enrollment in 1H ...

This Week's LA Deal Sheet - Vimarsana News

This Week's LA Deal Sheet

Thor Equities and a Danish pension fund buy a Santa Fe Springs cold storage facility for $85M, plus other need-to-know deals.

Source: bisnow.com
Success of unicorns like Matillion and Wejo helps UK tech ecosystem hit $1 trillion valuation - Vimarsana News

Success of unicorns like Matillion and Wejo helps UK tech ecosystem hit $1 trillion valuation

The UK has become the third country to have a tech sector which has surpassed the $1tn valuation mark, with 13 decacorns worth more than $10bn.

Cell therapy, AI drug discovery highlight 2021's record year in biotech IPOs - Vimarsana News

Cell therapy, AI drug discovery highlight 2021's record year in biotech IPOs

The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were hot categories of newly public companies, but even though IPOs reached record levels this year that streak is not expected to continue in 2022.